https://orcid.org/0000-0001-5805-2469
References
- Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med. 2023;29:344–347. doi:10.1038/s41591-022-02162-x
- Gangavarapu K, Latif AA, Mullen JL, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. Nat Methods. 2023;20:512–522. doi:10.1038/s41592-023-01769-3
- Chalkias S, Harper C, Vrbicky K, et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med. 2022;387:1279–1291. doi:10.1056/NEJMoa2208343
- Chalkias S, Eder F, Essink B, et al. Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat Med. 2022;28:2388–2397. doi:10.1038/s41591-022-02031-7
- Collier AY, Miller J, Hachmann NP, et al. Immunogenicity of BA.5 bivalent mRNA vaccine boosters. N Engl J Med. 2023;388:565–567. doi:10.1056/NEJMc2213948
- World Health Organization. (2023, May 18). Statement on the antigen composition of COVID-19 vaccines.
- Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020;369:806–811. doi:10.1126/science.abc6284
- Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205–1211. doi:10.1038/s41591-021-01377-8
- Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23:186–193. doi:10.1038/s41590-021-01122-w
- Keeton R, Tincho MB, Ngomti A, et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022;603:488–492. doi:10.1038/s41586-022-04460-3